A possible role for familial thrombophilia in women with polycystic ovarian syndrome

References

• Solomon CG. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol Metab Clin North Am 1999;28:247–263.
   PubMed Web of Science ®Google Scholar
• Goldenberg N, Glueck C. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation. Minerva Ginecol 2008;60:63–75.
   PubMedGoogle Scholar
• Tsanadis G, Vartholomatos G, Korkontzelos I, Avgoustatos F, Kakosimos G, Sotiriadis A, Tatsioni A, Eleftheriou A, Lolis D. Polycystic ovarian syndrome and thrombophilia. Hum Reprod 2002;17:314–319.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Wang P, Fontaine RN, Sieve-Smith L, Tracy T, Moore SK. Plasminogen inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 1999;48:1589–1595.
   PubMed Web of Science ®Google Scholar
• Atimo WU, Condon J, Adekanmi O, Friend J, Wilkin TJ, Archibald G. Are women with polycystic ovary syndrome resistant to activated protein C? Fertil Steril 2000;74:1229–1232.
   PubMedGoogle Scholar
• Rosendaal FR. Thrombosis series: venous thrombosis: a multicausal disease. Lancet 1999;353:1167–1173.
   PubMed Web of Science ®Google Scholar
• Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. USA: A Wolters Kluwer Company2005. pp 1086–1088.
   Google Scholar
• Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, Blumenfeld Z. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997;97:551–554.
   PubMed Web of Science ®Google Scholar
• Atimo W, Fox R, Condon J, Shaw S, Friend JR, Prentice AG, Wilkin TJ. Raised PAI-1 is not an independent risk factor in women with polycystic ovary syndrome. Clin Endocrinol 2000;52:487–492.
   PubMedGoogle Scholar
• Hervig T, Haram K, Sandset PM. Deep venous thrombosis in pregnant women. Tidsskr Nor Laegeforen 1998;118:4093–4097.
   PubMedGoogle Scholar
• Younis JS, Ohel G, Brenner B, Ben-Ami M. Familial thrombophilia-the scientific rationale for thrombophylaxis in recurrent pregnancy loss? Hum Reprod 1997;12:1389–1390.
   PubMedGoogle Scholar
• Tai J, Schliamser LM, Lcibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 1999;14:1624–1627.
   PubMedGoogle Scholar
• James AH. Prevention and management of venous thromboembolism in pregnancy. Am J Med 2007;120:S26–S34.
   PubMedGoogle Scholar
• A Working Group on Behalf of the Obstetric Medicine Group of Australasia. Anticoagulation in pregnancy and the puerperium. Med J Aust 2001;175:258–263.
   PubMedGoogle Scholar
• Kujovich JL. Thrombophilia and pregnancy complications. Am J Obstet Gynecol 2004;191:412–424.
   PubMed Web of Science ®Google Scholar
• Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R, McCarthy M. The genetic basis of polycystic ovary syndrome. Hum Reprod 1997;12:2641–2648.
   PubMed Web of Science ®Google Scholar
• Ghosh K, Shetty Sh, Vora S, Salvi V. Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: effect of unfractionated heparin and low-molecular weight heparin. Clin Appl Thromb Hemost 2008;14:174–179.
   PubMedGoogle Scholar
• Brenner, B. Inherited thrombophilia and pregnancy loss. Thromb Haemost 1999;82:634–640.
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-sponsored PCOS workshop group. Revised 2003 consensus on diagnosis criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
   PubMedGoogle Scholar
• Glueck CJ, Wang P, Bornovali S, Glodenberg N, Sieve L. Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism 2003;52:1627–1632.
   PubMed Web of Science ®Google Scholar
• Vrbíková J, Tallová J, Biciková M, Dvoráková K, Hill M, Stárka L. Plasma thiols and androgen levels in polycystic ovary syndrome. Clin Chem Lab Med 2003;41:216–221.
   PubMedGoogle Scholar
• Oktem M, Ozcimen EE, Uckuyu A, Esinler I, Pamuk B, Bayraktar N, Kulaksizoglu S, Zeyneloglu HB. Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril 2009;91:2545–2550.
   PubMed Web of Science ®Google Scholar
• Gillum R. Distribution of serum total homocysteine and its association with diabetes and cardiovascular risk factors of the insulin resistance syndrome in Mexican American men: the third national health and nutrition examination survey. Nutr J 2003;5:6.
   Google Scholar
• Sohrabvand F, Lankarani M, Golestan B, Haghollahi F, Asgarpoor L, Badamchi Z, Masoomi M, Javadi E. Serum homocysteine levels in PCOS patients versus healthy women. J Reprod Infertil 2008;9:334–341.
   Google Scholar
• James DK, Weneri CP, Steer PhJ, Gonik B. High risk pregnancy: management options. 3th ed. USA: Elsevier Inc2006. pp 926–927, 938–941.
   Google Scholar
• Glueck CJ, Sieve L, Zhu B, Wang P. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first- trimester miscarriage in women with polycystic ovary syndrome. Metabolism 2006;55:345–352.
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Aregawi D, Goldenberg N, Golnik KC, Sieve L, Wang P. Idiopatic intracranial hypertension, polycystic ovary syndrome, and thrombophilia. J Lab Clin Med 2005;145:72–82.
   PubMed Web of Science ®Google Scholar